Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals (AMRX) with a Buy rating and $12 price target The firm expects continued momentum across the portfolio and sees upside to consensus estimates. Goldman sees Amneal’s generics segment remaining the key component and driver of EBITDA growth, driven by the company’s strong product pipeline, including biosimilar and sterile injectable launches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals recalls Sulfamethoxazole/Trimethoprim tablets, FDA says
- Amneal Pharmaceuticals announces FDA approved Brekiya injection
- Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting
- Amneal Pharmaceuticals, Apiject announce strategic collaboration
- Amneal Pharmaceuticals Reports Strong Q1 2025 Results